Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Neuroscience., Oct;194:189-94 (2011)
Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
Neurology., Jun;50(6):1630-6 (1998)
Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum.
Neurosci. Lett., Jun;228(2):119-22 (1997)
Sensory and cognitive functions of the basal ganglia.
Curr. Opin. Neurobiol., Apr;7(2):157-63 (1997)
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Neurosci. Lett., Jan;222(2):138-40 (1997)
Alterations in intralaminar and motor thalamic physiology following nigrostriatal dopamine depletion.
Brain Res., Dec;742(1-2):25-33 (1996)
Alterations in pallidal neuronal responses to peripheral sensory and striatal stimulation in symptomatic and recovered parkinsonian cats.
Brain Res., Dec;705(1-2):1-14 (1995)
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.
Neurodegeneration., Sep;4(3):245-55 (1995)
GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
J. Neurosci. Res., Sep;42(1):117-23 (1995)
Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys.
Pharmacol. Biochem. Behav., Aug;51(4):617-22 (1995)
GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
Neurology., Jun;45(6):1149-54 (1995)
Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
Neuropharmacology., May;34(5):489-93 (1995)
Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
Brain Res., Mar;674(2):260-4 (1995)
Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism.
Neurodegeneration., Mar;4(1):87-92 (1995)
Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Brain Res., Feb;672(1-2):112-7 (1995)
Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.
Brain Res., Nov;663(1):140-4 (1994)
Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys.
Pharmacol. Biochem. Behav., May;48(1):235-40 (1994)
Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism.
Brain Res., Apr;643(1-2):86-91 (1994)
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
Neurology., Apr;44(4):748-50 (1994)
GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment.
Brain Res., Mar;640(1-2):308-15 (1994)
Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys.
Behav. Brain Res., Feb;60(2):115-24 (1994)
GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
Brain Res., Feb;636(2):353-6 (1994)
Spontaneous functional recovery from parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons.
Brain Res. Bull., 34(3):309-12 (1994)
LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
Neuroreport., Nov;5(2):103-4 (1993)
Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic, and recovered MPTP-treated cats.
J. Neurosci., Oct;13(10):4372-8 (1993)
Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys.
Brain Res., Jul;615(2):351-4 (1993)
Gangliosides and neurological diseases.
BMJ., Jan;306(6871):204 (1993)
Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion.
Neurology., Aug;42(8):1565-72 (1992)
Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Neuropharmacology., Feb;31(2):185-92 (1992)
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
J. Neurosci. Res., Jan;31(1):112-9 (1992)
Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Brain Res., Aug;556(2):292-6 (1991)
Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms.
Neurosci. Lett., Jun;127(1):49-52 (1991)
Responses of striatal neurons to peripheral sensory stimulation in symptomatic MPTP-exposed cats.
Brain Res., Mar;544(2):297-302 (1991)
Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder.
J. Child Neurol., 6 Suppl:S82-9 (1991)
Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats.
Neuroscience., 44(2):421-9 (1991)
Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys.
Brain Res., Nov;534(1-2):25-36 (1990)
Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.
Brain Res., Jun;519(1-2):122-8 (1990)
Anatomical evidence of the projection of pontine omnipause neurons to midbrain regions controlling vertical eye movements.
J. Comp. Neurol., Nov;289(4):610-25 (1989)
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Pharmacol. Biochem. Behav., Sep;34(1):193-6 (1989)
GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.
Exp. Neurol., Aug;105(2):177-83 (1989)
MPTP-induced ventral mesencephalic cell loss in the cat.
Neurosci. Lett., Jul;101(3):258-62 (1989)
Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Brain., Dec;111 ( Pt 6):1265-85 (1988)
Dopaminergic dorsal raphe neurons in cats and monkeys are sensitive to the toxic effects of MPTP.
Neurosci. Lett., Nov;94(1-2):218-23 (1988)
Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain.
J. Neuropathol. Exp. Neurol., Jul;47(4):452-8 (1988)
Parkinson's disease: sensory and motor problems in arms and hands.
Neurology., Jun;37(6):951-6 (1987)
Interactions between the basal ganglia, the pontine parabrachial region, and the trigeminal system in cat.
Neuroscience., Oct;19(2):411-25 (1986)
A consideration of sensory factors involved in motor functions of the basal ganglia.
Brain Res., Jun;356(2):133-46 (1985)
Motor function of basal ganglia.
Neurology., Feb;34(2):262-3 (1984)